Agennix AG Gets Positive Results from Talactoferrin Trial

Agennix AG (Frankfurt Stock Exchange: AGX) has reported results from the talactoferrin randomized, double-blind, placebo-controlled Phase 2 trial in severe sepsis. The trial evaluated talactoferrin versus placebo in 190 adult patients with severe sepsis enrolled at 25 leading centers across the U.S. Patients in both arms also received standard of care treatment for severe sepsis in an intensive care unit (ICU) setting. The trial achieved its primary endpoint of a reduction in 28-day all-cause mortality. The trial showed a 45% reduction in the 28-day all-cause mortality from 26.6% in the placebo arm to 14.6% in the talactoferrin arm (two-tailed p-value =3D 0.04, odds ratio by logistic regression analysis =3D 0.47). "We are very excited to see such compelling results with talactoferrin in severe sepsis, a life-threatening and notoriously hard-to-treat disease," said Rajesh Malik, M.D., Chief Medical Officer. "There are currently very limited treatment options available, with only one drug in the U.S. approved specifically for severe sepsis, a disease that results in hundreds of thousands of deaths each year in the U.S. and Europe alone. Given the strength of these clinical trial results, we plan to talk with regulatory authorities, as well as key opinion leaders and potential partners, about advancing talactoferrin for this indication."